Pharmatest Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
2ndary - Private
Pharmatest General Information
Description
Provider of preclinical efficacy services intended to help with early, cost-effective drug development procedures. The company's translational research services are offered towards addressing the diseases with unmet clinical needs in therapeutic areas of oncology and skeletal disease models, enabling medical researchers to reduce the number of drug candidate failures in clinical trials.
Contact Information
Website
www.pharmatest.comCorporate Office
- Itäinen Pitkäkatu 4C
- 5th floor
- 20520 Turku
- Finland
Corporate Office
- Itäinen Pitkäkatu 4C
- 5th floor
- 20520 Turku
- Finland
Pharmatest Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Oct-2022 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 13-Jan-2014 | Completed | Pre-Clinical Trials | |||
| 1. Later Stage VC | 01-Jan-2014 | Completed | Pre-Clinical Trials |
Pharmatest Patents
Pharmatest Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2711007-A1 | 4-aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer | Inactive | 19-Sep-2012 | ||
| EP-2711009-A1 | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer | Inactive | 19-Sep-2012 | ||
| EP-2711008-A1 | N6,n6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer | Inactive | 19-Sep-2012 | ||
| JP-2012505666-A | Methods and uses involving nav3 gene abnormalities and abnormal expression of multiple genes | Active | 20-Oct-2008 | ||
| JP-5819728-B2 | Methods and uses involving nav3 gene abnormalities and abnormal expression of multiple genes | Inactive | 20-Oct-2008 | C12Q1/6886 |
Pharmatest Signals
Pharmatest Acquisitions (2)
Pharmatest’s most recent deal was a Merger/Acquisition with Genolyze. The deal was made on 30-Dec-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Genolyze | 30-Dec-2009 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| Orthotopix | 30-Dec-2009 | Merger/Acquisition | Discovery Tools (Healthcare) |
Pharmatest FAQs
-
When was Pharmatest founded?
Pharmatest was founded in 1998.
-
Where is Pharmatest headquartered?
Pharmatest is headquartered in Turku, Finland.
-
What is the size of Pharmatest?
Pharmatest has 23 total employees.
-
What industry is Pharmatest in?
Pharmatest’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Pharmatest a private or public company?
Pharmatest is a Private company.
-
What is Pharmatest’s current revenue?
The current revenue for Pharmatest is .
-
How much funding has Pharmatest raised over time?
Pharmatest has raised $684K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process